Compare IRON & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRON | TWST |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.0B |
| IPO Year | N/A | 2018 |
| Metric | IRON | TWST |
|---|---|---|
| Price | $73.54 | $47.47 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 9 |
| Target Price | ★ $110.08 | $50.22 |
| AVG Volume (30 Days) | 526.7K | ★ 1.5M |
| Earning Date | 02-26-2026 | 02-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $391,557,000.00 |
| Revenue This Year | N/A | $16.77 |
| Revenue Next Year | N/A | $15.06 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 18.59 |
| 52 Week Low | $30.82 | $23.30 |
| 52 Week High | $99.50 | $54.74 |
| Indicator | IRON | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 41.49 | 65.83 |
| Support Level | $76.00 | $44.91 |
| Resistance Level | $83.93 | $49.72 |
| Average True Range (ATR) | 4.20 | 2.54 |
| MACD | 0.20 | 0.28 |
| Stochastic Oscillator | 13.69 | 77.73 |
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.